{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:24:34Z","timestamp":1775064274296,"version":"3.50.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T00:00:00Z","timestamp":1522972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1093\/jac\/dky124","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T20:09:55Z","timestamp":1521230995000},"page":"2021-2029","source":"Crossref","is-referenced-by-count":54,"title":["Efficacy and safety of ceftazidime\/avibactam: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"73","author":[{"given":"Neta","family":"Sternbach","sequence":"first","affiliation":[{"name":"Medicine D, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaara","family":"Leibovici Weissman","sequence":"additional","affiliation":[{"name":"Medicine D, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel"},{"name":"Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomer","family":"Avni","sequence":"additional","affiliation":[{"name":"Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel"},{"name":"Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafna","family":"Yahav","sequence":"additional","affiliation":[{"name":"Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel"},{"name":"Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,4,6]]},"reference":[{"key":"key\n\t\t\t\t20180720035914_dky124-B1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2047-2994-1-11","article-title":"Ready for a world without antibiotics? The Pensi\u00e8res Antibiotic Resistance Call to Action","volume":"1","author":"Carlet","year":"2012","journal-title":"Antimicrob Resist Infect Control"},{"key":"key\n\t\t\t\t20180720035914_dky124-B2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/11533040-000000000-00000","article-title":"Infections with extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices","volume":"70","author":"Pitout","year":"2010","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20180720035914_dky124-B3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4065\/mcp.2010.0674","article-title":"Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa","volume":"86","author":"Kanj","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t20180720035914_dky124-B4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1473-3099(09)70054-4","article-title":"The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria","volume":"9","author":"Nordmann","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180720035914_dky124-B5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ijmm.2010.04.005","article-title":"Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens","volume":"300","author":"Pfeifer","year":"2010","journal-title":"Int J Med Microbiol"},{"key":"key\n\t\t\t\t20180720035914_dky124-B6","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/dkx438","article-title":"Activity of ceftazidime\/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16","volume":"73","author":"Livermore","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180720035914_dky124-B7","article-title":"Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review","author":"Tuon","year":"2017","journal-title":"Infection"},{"key":"key\n\t\t\t\t20180720035914_dky124-B8","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","article-title":"New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?","volume":"23","author":"Wright","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180720035914_dky124-B9","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180720035914_dky124-B10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180720035914_dky124-B11","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20180720035914_dky124-B12","author":"Higgins","year":"2011"},{"key":"key\n\t\t\t\t20180720035914_dky124-B13","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/jac\/dkw135","article-title":"Addressing resistance to antibiotics in systematic reviews of antibiotic interventions","volume":"71","author":"Leibovici","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180720035914_dky124-B14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180720035914_dky124-B15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180720035914_dky124-B16","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180720035914_dky124-B17","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180720035914_dky124-B18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180720035914_dky124-B19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180720035914_dky124-B20","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"key\n\t\t\t\t20180720035914_dky124-B21","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: rECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180720035914_dky124-B22","author":"Mendes"},{"key":"key\n\t\t\t\t20180720035914_dky124-B23","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1128\/AAC.01173-15","article-title":"\u03b2-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: clinical efficacies analyzed against subsets of molecularly characterized isolates","volume":"60","author":"Mendes","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180720035914_dky124-B24","doi-asserted-by":"crossref","first-page":"e02447","DOI":"10.1128\/AAC.02447-16","article-title":"Molecular \u03b2-lactamase characterization of aerobic Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials for complicated intra-abdominal infections, with efficacies analyzed against susceptible and resistant subsets","volume":"61","author":"Mendes","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180720035914_dky124-B25","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01820-16","article-title":"In vitro activity of ceftazidime-avibactam against isolates in a phase 3 open-label clinical trial for complicated intra-abdominal and urinary tract infections caused by ceftazidime-nonsusceptible Gram-negative pathogens","volume":"61","author":"Stone","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180720035914_dky124-B26","first-page":"1396","article-title":"In vitro activity of ceftazidime\/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections","volume":"72","author":"Stone","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180720035914_dky124-B27","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Second Informational Supplement M100-S22","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"key\n\t\t\t\t20180720035914_dky124-B28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/mdr.2005.11.165","article-title":"Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients","volume":"11","author":"Kwak","year":"2005","journal-title":"Microb Drug Resist"},{"key":"key\n\t\t\t\t20180720035914_dky124-B29","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1128\/AAC.01020-07","article-title":"Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality","volume":"52","author":"Schwaber","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180720035914_dky124-B30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/jac\/dku351","article-title":"\u03b2-Lactam\/\u03b2-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials","volume":"70","author":"Shiber","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180720035914_dky124-B31","doi-asserted-by":"crossref","DOI":"10.1089\/sur.2016.283","article-title":"Mortality rate and antibiotic resistance in complicated diverticulitis: report of 272 consecutive patients worldwide: a prospective cohort study","author":"Coccolini","year":"2017","journal-title":"Surg Infect (Larchmt)"},{"key":"key\n\t\t\t\t20180720035914_dky124-B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1749-7922-8-1","article-title":"Complicated intra-abdominal infections in a worldwide context: an observational prospective study (CIAOW Study)","volume":"8","author":"Sartelli","year":"2013","journal-title":"World J Emerg Surg"},{"key":"key\n\t\t\t\t20180720035914_dky124-B33","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180720035914_dky124-B34","doi-asserted-by":"crossref","first-page":"e008838","DOI":"10.1136\/bmjopen-2015-008838","article-title":"External validity of a randomised controlled trial on the treatment of severe infections caused by MRSA","volume":"5","author":"Paul","year":"2015","journal-title":"BMJ Open"},{"key":"key\n\t\t\t\t20180720035914_dky124-B35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1473-3099(17)30748-X","article-title":"Ceftazidime-avibactam versus meropenem for the treatment of nosocomial pneumonia","volume":"18","author":"Kalil","year":"2017","journal-title":"Lancet Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/8\/2021\/25178734\/dky124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T11:18:02Z","timestamp":1603970282000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/8\/2021\/4962462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,6]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,4,6]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky124","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,4,6]]}}}